Artificial Intelligence Predicts Survival in Epithelial Ovarian Cancer
Radiomic Prognostic Vector IDs patients with median overall survival of less than 2 years.
Ovarian Cancer
Cancer Screening Nonadherence May Be Associated With Increase in Overall Mortality
Nonadherence to protocol screenings in a screening trial for multiple cancers may be linked to higher overall mortality, excluding mortality due to cancers studied in the trial.
Lynparza OK’d as First-Line Maintenance of BRCA-Mutated Advanced Ovarian CA
Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor is already approved to treat certain breast, epithelial ovarian, fallopian tube or primary peritoneal cancers based on an FDA-approved companion diagnostic.
Primary Care May Aid Genetic Counseling Referral for Ovarian Cancer Survivors
A pair of new case-finding strategies may help general practitioners identify and refer patients and survivors of ovarian cancer to genetic counseling and DNA testing.
Ovarian Cancer Screening: Assessing the Risks and Benefits
Gynecologists may be more likely to change their beliefs about ovarian cancer screening when presented with more detailed evidence about screening benefits and harms.
Ovarian Cancer Risk Linked to Ultrasonographic Characteristics of Ovarian Masses
Pelvic ultrasonography was used to distinguish between simple cysts and more complex cysts or solid masses, which are associated with an increased risk of ovarian cancer.
Many Women Have Not Heard of Ovarian Cancer Before Diagnosis
Nine in 10 women experience multiple symptoms prediagnosis; 8 in 10 of them consult a doctor.
Screening for Ovarian Cancer in Low-Risk Women Influenced by Clinician Personal Experience
Nonprofessional experience with cancer may be associated with a lack of adherence to ovarian cancer screening guidelines.
Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer
Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.
Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer
Patients in the real world setting were initiated at a lower dose and experienced fewer side effects than trial participants.
Next post in Oncology
